Conexeu Sciences Inc.

CNXU

NASDAQHealthcareBiotechnology

在 GoAI 中打开

收盘时

US$7.81

−US$1.08 · -12.15%

8月24日 16:00 ET

盘后

US$7.75

−US$0.06 · -0.77%

8月24日 19:30 ET

盘中时间采用ET。市场数据可能有所延迟。

公司概况

Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Miles Harrison
上市以来: 2026年5月21日
雇员: 4

市场位置

日内区间

当前US$7.81，

US$7.70US$9.1885

52周区间

当前US$7.81，

US$6.85US$18.79

开盘价: US$8.77
前收盘价: US$8.89
成交量: 41.13万; 3.02× 平均值
平均成交量: 13.6万; 日均成交量
市值: 2.09亿 USD
贝塔: 0.51; 市场参考 1
50天平均值: US$9.7068; 低于平均水平-19.54%
200天平均值: US$10.70; 低于平均水平-27.01%

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$20.00

上涨空间 156.08%

过去 12 个月12个月预测最高：US$20.00平均的：US$20.00最低：US$20.00

CNXU 消息

globenewswire.com2026年8月18日

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform

阅读源码

prnewswire.com2026年7月15日

The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.

/PRNewswire/ -- Equity Insider News Commentary - Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next

阅读源码

globenewswire.com2026年7月14日

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.

阅读源码

globenewswire.com2026年7月7日

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the evidence…

阅读源码

globenewswire.com2026年6月25日

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre

阅读源码

seekingalpha.com2026年6月24日

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance…

阅读源码